Eleven Biotherapeutics
March 3, 2014
PDF
Add to Briefcase

Eleven Biotherapeutics Appoints Paul Chaney to Its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Paul Chaney, President and Chief Executive Officer of PanOptica, Inc., to the Company's board of directors.

"Paul brings nearly 30 years of experience in the pharmaceutical industry, including 19 years of ophthalmic pharmaceutical development and commercial leadership experience, to Eleven," said Abbie Celniker, Ph.D., President and Chief Executive Officer of Eleven. "Paul's skills and experience in leading ophthalmology-focused biotechnology companies and pharmaceutical company business units will be valuable to Eleven as the Company advances its ophthalmic developmentĀ programs."

Paul Chaney is President and Chief Executive Officer of PanOptica, a private, venture-backed biopharmaceutical company focused on developing innovative ophthalmic therapeutics. Prior to co-founding PanOptica in 2009, Paul was Executive Vice President of OSI Pharmaceuticals, Inc. and President of (OSI) Eyetech, Inc., OSI Pharmaceuticals' wholly-owned eyecare subsidiary. He joined Eyetech Pharmaceuticals, Inc. as Chief Operating Officer in 2003. Prior to joining Eyetech, Paul held a variety of senior management positions at Pharmacia Corporation, including Vice President of the Global Ophthalmology Business and Vice President of Global Pharmaceutical Ophthalmology. He began his career as a sales representative for The Upjohn Company in 1980. Paul earned a dual degree in Biological Sciences and English from the University of Delaware.

About Eleven Biotherapeutics

Eleven Biotherapeutics is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's therapeutic approach is based on the role of cytokines in diseases of the eye, the Company's understanding of the structural biology of cytokines and the Company's ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, advancement of the Company's development programs, clinical development of the Company's therapeutic candidates and future value or contributions of individuals to the Company, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from ongoing clinical trials, whether results of early clinical trials will be indicative of the results of future trials and other factors discussed in the "Risk Factors" section of the Company's prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) on February 6, 2014. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Eleven Biotherapeutics
Cameron Wheeler, PhD, 617-858-0927
cameron@elevenbio.com
or
Media:
The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com

Source: Eleven Biotherapeutics

News Provided by Acquire Media